Kiniksa insider Paolini exercises options at $3.80, sells at $32.55
Rhea-AI Filing Summary
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating a pre-established trading program
- Option is fully vested and exercisable, and the filer discloses willingness to provide detailed trade-level pricing
Negative
- Reported sale of 29,325 Class A Ordinary Shares, which reduces the reporting person’s beneficial ownership
- Post-transaction beneficial ownership figures include lower reported holdings (57,403 Class A shares) compared with pre-transaction totals
Insights
Routine option exercise and sale disclosed under a documented 10b5-1 plan; transparency is key for investors.
The filing shows an insider exercised 29,325 options at a low exercise price and sold the resulting shares at a materially higher weighted average price, producing potential cash proceeds. Because the transactions were processed under a Rule 10b5-1 plan and the option is confirmed fully vested, this appears to be a pre-planned, compliance-oriented disposition rather than an opportunistic market-timing sale. The filer’s offer to provide per-trade pricing supports transparency. Impact to outstanding float appears limited given the reported post-transaction ownership figures.
Disclosure follows standard governance practices; documented plan and attorney-in-fact signature improve procedural clarity.
The Form 4 documents execution under a written 10b5-1 plan and includes an attorney-in-fact signature, which addresses procedural governance and insider-trading compliance considerations. The filing also discloses option vesting status and post-transaction ownership counts, enabling shareholders to assess insider alignment with company performance. While insider sales can raise investor questions, the presence of a pre-existing plan and explicit trade pricing information reduces ambiguity about intent.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 29,325 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 29,325 | $3.80 | $111K |
| Sale | Class A Ordinary Share | 29,325 | $32.55 | $955K |
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.13 and $33.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
